BioSpace News Archive

Royalty Pharma plc and Ferring Pharmaceuticals announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September.

XNK Therapeutics AB announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia.

CancerVAX, Inc announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher.

Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ultrasound and across cardiac care to help improve clinical confidence and increase efficiency.

Biovica International, active in cancer diagnostics, announces the initiation of a prospective clinical trial to study the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of metastatic breast cancer patients.

CollPlant Biotechnologies (NASDAQ: CLGN) today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs.

Bionoid Pharma, Inc. is pleased to announce the extension of the effective period of a Letter of Intent, along with its exclusivity provisions, with Global Alerts Corp., as initially disclosed on March 22, 2023.

Societal CDMO, Inc. announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock at a public offering price of $0.40 per share of common stock, for gross proceeds of $8.3 million, before underwriting discounts and commissions and offering expenses.

AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS) today announced that it has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application No. 17/006,685, titled “Neurotoxin Compositions for Use in Treating Headache” (the “Application”), which involves the Company’s lead asset, ABP-450 (prabotulinumtoxinA) injection.